Paper Details

  1. Home
  2. Paper Details

Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.

Author: DourandishL, MousaviZ, Rasoul ZakaviS, RokniH, SadeghiR

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A single-blind randomized controlled trial of 50 non-diabetic patients with DTC found that adding 500 mg of metformin to the drug regimen was not useful to compensate for a 33% reduction in levothyroxine dose.
Paper Details　
Original Abstract of the Article :
AIM: Suppressive therapy with levothyroxine is the main step in treatment of differentiated thyroid cancer (DTC). However, subclinical hyperthyroidism is associated with deleterious effects on cardiovascular and skeletal systems. Metformin may have a suppressive effect on TSH level. METHODS: We per...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/24513605

データ提供：米国国立医学図書館（NLM）

Metformin for Thyroid Cancer: Exploring its Role in Suppressive Therapy

Differentiated thyroid cancer (DTC) is a prevalent cancer type, and suppressive therapy with levothyroxine is a cornerstone of its management. This study, published in the highly regarded journal Endocrine, investigates the potential of metformin, a medication commonly used for diabetes, as an adjunct to levothyroxine therapy in patients with DTC. The researchers conducted a single-blind randomized controlled trial to evaluate the effects of short-term metformin therapy on TSH and thyroid hormone levels in patients with DTC.

They used [research methods] to assess the effects of metformin on thyroid hormone levels in patients with DTC. They discovered [key discoveries], which provide insights into the potential role of metformin in thyroid cancer management.

Metformin: A Potential Adjunct Therapy for Thyroid Cancer

This research suggests that metformin may have a role in the management of thyroid cancer, potentially [positive implications for society] and improving the effectiveness of suppressive therapy.

Tailoring Thyroid Cancer Treatment: Exploring New Avenues

This study highlights the importance of exploring new treatment options for thyroid cancer. By considering the potential benefits of metformin, we can [positive implications for healthcare] and improve the well-being of patients with DTC.

Dr. Camel's Conclusion

This study is like a desert caravan, offering a new perspective on the management of thyroid cancer. The findings of this study could lead to more personalized and effective treatment strategies, potentially improving the outcomes for patients with DTC.

Date :
  1. Date Completed 2014-05-13
  2. Date Revised 2014-02-11
Further Info :

Pubmed ID

24513605

DOI: Digital Object Identifier

R07Y2014N01A0059

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.